Please try another search
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Keith C. Ferdinand | - | 2016 | Member of Scientific & Clinical Advisory Board |
Carole Wassermann | 57 | 2018 | Director |
Alexandre Persu | - | - | Member of Scientific & Clinical Advisory Board |
Atul Pathak | - | 2022 | Member of Scientific & Clinical Advisory Board |
George L. Bakris | - | 2022 | Member of Scientific & Clinical Advisory Board |
Francois Durvye | - | 2022 | Director |
Gregory Y.H. Lip | - | 2022 | Member of Scientific & Clinical Advisory Board |
François Pelen | 66 | 2022 | Independent Director |
Lionel Segard | 55 | 2006 | Director |
Jean-Philippe Milon | 63 | 2018 | CEO, MD & Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review